Your Manuscript in Review: It is never an idle question

(by drugmonkey) Aug 22 2018

I was trained to respond to peer review of my submitted manuscripts as straight up as possible. By this I mean I was trained (and have further evolved in training postdocs) to take every comment as legitimate and meaningful while trying to avoid the natural tendency to view it as the work of an illegitimate hater. This does not mean one accepts every demand for a change or alters one's interpretation in preference for that of a reviewer. It just means you take it seriously.

If the comment seems stupid (the answer is RIGHT THERE), you use this to see where you could restate the point again, reword your sentences or otherwise help out. If the interpretation is counter to yours, see where you can acknowledge the caveat. If the methods are unclear to the reviewer, modify your description to assist.

I may not always reach some sort of rebuttal Zen state of oneness with the reviewers. That I can admit. But this approach guides my response to manuscript review. It is unclear that it guides everyone's behavior and there are some folks that like to do a lot of rebuttal and relatively less responding. Maybe this works, maybe it doesn't but I want to address one particular type of response to review that pops up now and again.

It is the provision of an extensive / awesome response to some peer review point that may have been phrased as a question, without incorporating it into the revised manuscript. I've even seen this suboptimal approach extend to one or more paragraphs of (cited!) response language.

Hey, great! You answered my question. But here's the thing. Other people are going to have the same question* when they read your paper. It was not an idle question for my own personal knowledge. I made a peer review comment or asked a peer review question because I thought this information should be in the eventual published paper.

So put that answer in there somewhere!

___
*As I have probably said repeatedly on this blog, it is best to try to treat each of the three reviewers of your paper (or grant) as 33.3% of all possible readers or reviewers. Instead of mentally dismissing them as that weird outlier crackpot**.

**this is a conclusion for which you have minimal direct evidence.

5 responses so far

Anti-Nepotism Rules

(by drugmonkey) Aug 21 2018

The University of Texas, Austin rule states, in part:

No University employee may approve, recommend, or otherwise take action with regard to the appointment, reappointment, promotion, salary or supervision of a close relative as defined by this policy.

which is not, I think, uncommon.

So: No hiring your spouse or supervising your spouse.

There is also some weasel language that could potentially undercut the policy in practice. If you become married or a spouse transfers under your putative supervision, there has to be notification but it is allowed. The the management and oversight of this nepotistic employee goes to the PI’s boss.

This is likely how a thin veneer of red tape covers the case of a spouse working in the lab of an appointed Professorial rank person.

So nepotism is officially bad, but University policy has enough wiggle room to permit a de facto case of hiring and supervision of one's spouse.

In a lab the idea of getting meaningful supervisory oversight from the PI’s supervisor is a joke. It in no way can mitigate preferential treatment and in fact justifies it. The PI can set work hours, discipline for poor performance and even fire everyone *except* the spouse.

14 responses so far

Of course the NIH can strong-arm Universities if they really want to

(by drugmonkey) Aug 16 2018

I think the NIH should more frequently use the power of the purse to change the behavior of Universities. I expressed this recently in the context of a Congressional demand for information from the NIH Director on the NIH oversight of the civil rights obligations of their awardee institutions. I have probably expressed this in other contexts as well. Before the invention of the K99/R00 one saw handwringing from the NIH about how Universities wouldn't hire less experienced PhDs and this was the RealProblem accounting for the time-to-first-R01 stat. My observation at the time was that if the NIH was serious they could just ask Universities for their hiring stats and tell ones that didn't hire enough young faculty that they were going to go to the back of the line for any special consideration awards.

This could also apply to occasionally bruited NIH concerns about women, underrepresented groups and other classes of folks not typically treated well by Universities. Exhibit lower than average hiring or promoting of women or URM professors? You go to the back of the special consideration line, sorry.

My suggestions are typically met with "we can't" when I am talking to various NIH Program types and various grades of "they can't" when talking to extramural folks about it.

Of course the NIH can.

They already do.

One very specific case of this is the K99/R00 award when it comes time for administrative review of the R00 phase hiring package. If the NIH finds the proposed hiring package to be deficient they can refuse to award the R00. I have no idea how many times this has been invoked. I have no idea how many times an initial offer of a University has been revised upwards because NIH program balked at the initial offer. But I am confident it has happened at least once. And it is certainly described extensively as a privilege the NIH reserves to itself.

A more general case is the negotiation of award under unusual circumstances. The NIH allows exemptions from the apparent rules all the time. (I say "apparent" because of course NIH operates within the rules at all times. There are just many rules and interpretations of them, I suspect.) They can, and do, refuse to make awards when an original PI is unavailable and the Uni wants to substitute someone else. They cut budgets and funded years. They can insist that other personnel are added to the project before they will fund it. They will pick up some but not other awards with end of year funds based on the overhead rate.

These things have a manipulating effect on awardee institutions. It can force them to make very specific and in some cases costly (startup packages, equipment, space) changes from what they would otherwise have done.

This is NIH using the power of the purse to force awardee institutions to do things. They have this power.

So the only question is whether they choose to use it, for any particular goal that they claim to be in favor of achieving.

2 responses so far

GAO report shows the continued NIH grant funding disparity for underrepresented PIs

(by drugmonkey) Aug 15 2018

A comment from pielcanelaphd on a prior post tips us off to a new report (PDF) from the General Accountability Office, described as a report to Congressional Committees.

The part of the report that deals with racial and ethnic disparities is mostly recitation of the supposed steps NIH has been taking in the wake of the Ginther report in 2011. But what is most important is the inclusion of Figure 2, an updated depiction of the funding rate disparity.
GAO-18-545:NIH RESEARCH Action Needed to Ensure Workforce Diversity Strategic Goals Are Achieved

These data are described mostly as the applicant funding rate or similar. The Ginther data focused on the success rate of applications from PIs of various groups. So if these data are by applicant PI and not by applications, there will be some small differences. Nevertheless, the point remains that things have not improved and PIs from underrepresented ethnic and racial groups experience a disparity relative to white PIs.

No responses yet

Senator Murray and Representative DeLauro Want to Know What NIH Is Doing About Sexual Harassment

(by drugmonkey) Aug 15 2018

Readers of this blog will not need too much reminder that sexual harassment and sex-based workplace discrimination are very much a problem in academic science. We have seen numerous cases of this sort of academic misconduct reach the national and sometimes international press in the past several years. Indeed, recent discussions on this blog have mentioned the cases of Thomas Jessell and Inder Verma as well as three cases at Dartmouth College.

In these cases, and ones of scientific fraud, I and others have expressed frustration that the NIH does not appear to use what we see as its considerable power of the purse and bully pulpit to discourage future misconduct. My view is that since NIH award is a privilege and not a right, the NIH could do a lot to help their recipient institutions see that taking cases of misconduct more seriously is in their (the recipient institution's) best interest. They could pull the grants associated with any PI who has been convicted of misconduct, instead of allowing the University to appoint a replacement PI. They could refuse to make any new awards or, less dramatically, make any exception pickups if they aren't happy with the way the University has been dealing with misconduct. They could focus on training grants or F-mech fellowships if they see a particular problem in the treatment of trainees. Etc. Lots of room to work since the NIH decides all the time to fund this grant and not that grant for reasons other than the strict order of review.

Well, two Democratic members of Congress have sent a letter (PDF) to NIH Director Francis Collins gently requesting* information on how NIH is addressing sexual harassment in the workplace. And the overall message is in line with the above belief that NIH can and should play a more active role in addressing sexual misconduct and harassment.

As pointed out in a Mike the Mad Biologist's post on this letter, these two Congresspeople have a lot of potential power if the Democrats return to the majority.

are ranking members of committees that oversee NIH funding–and if the Democrats take back the House or Senate, would be the leaders of those committees.

One presumes that the NIH will be motivated to take this seriously and offer up some significant response. Hopefully they can do this by what seems a rather optimistic deadline of 8/17/2018, given the letter was dated 8/06/2018.

The first 6 listed items to which NIH is being asked to response seem mostly to do with the workings of Intramural NIH, both Program and the IRP. Those are of less interest as a dramatic change, important as they are.

Most importantly, the letter puts the NIH squarely on the hook for the way that it ensures that the extramural awardee institutions are behaving. Perhaps obviously, the power of NIH to oversee issues of harassment at all of the Universities, Institutes and companies that they fund is limited. The main point of justification in this letter is the NOT-OD-15-152: Civil Rights Protections in NIH-Supported Research, Programs, Conferences and Other Activities.

To give you a flavor:

Federal civil rights laws prohibit discrimination on the basis of race, color, national origin, disability, and age in all programs and activities that receive Federal financial assistance, and prohibit discrimination on the basis of sex in educational programs or activities conducted by colleges and universities. These protections apply in all settings where research, educational programs, conferences, and other activities are supported by NIH, and apply to all mechanisms of support (i.e., grant awards, contracts and cooperative agreements). The civil rights laws protect NIH-supported investigators, students, fellows, postdocs, participants in research, and other individuals involved in activities supported by NIH.

The notice then goes on to list several specific statutes, some of which are referenced in footnotes to the letter.
The Murray/DeLauro letter concentrates on the obligation recipient institutions have to file an Assurance of Compliance with the Health and Human Services (NIH's parent organization) Office of Civil Rights and the degree to which NIH exercises oversight on these Assurances.

I think the motivations of Senatory Murray and Rep DeLauro are on full display in this passage (emphasis added).

"It therefore appears that NIH's only role...is confirming...institution has signed, dated, and mailed the compliance document....

This lack of engagement from NIH is particularly unacceptable in light of disturbing news reports that cases of sexual harassment in the academic sciences often involve high profile faculty offenders whose behavior is considered an 'open secret'.

...colleagues may have warned new faculty and students.....but institutions themselves take little to no action."

It is on.

__
*demanding

8 responses so far

NIH policy on A2 as A0 that I didn't really appreciate.

(by drugmonkey) Jul 26 2018

The NOT-OD-18-197 this week seeks to summarize policy on the submission of revised grant applications that has been spread across multiple prior notices. Part of this deals with the evolved compromise where applicants are only allowed to submit a single formal revision (the -xxA1 version) but are not prohibited from submitting a new (-01, aka another A0 version) one with identical content, Aims, etc.

Addendum A emphasizes rules for compliance with Requirements for New Applications. The first one is easy. You are not allowed an extra Introduction page. Sure. That is what distinguishes the A1, the extra sheet for replying.

After that it gets into the weeds. Honestly I would have thought this stuff all completely legal and might have tried using it, if the necessity ever came up.

The following content is NOT allowed anywhere in a New A0 Application or its associated components (e.g., the appendix, letters of support, other attachments):

Introduction page(s) to respond to critiques from a previous review
Mention of previous overall or criterion scores or percentile
Mention of comments made by previous reviewers
Mention of how the application or project has been modified since its last submission
Marks in the application to indicate where the application has been modified since its last submission
Progress Report

I think I might be most tempted to include prior review outcome? Not really sure and I've never done this to my recollection. Mention of prior comments? I mean I think I've seen this before in grants. maybe? Some sort of comment about prior review that did not mean the revision series.

Obviously you can accomplish most of this stuff within the letter of the law by not making explicit mention or marking of revision or of prior comments. You just address the criticisms and if necessary say something about "one might criticize this for...but we have proposed....".

The Progress Report prohibition is a real head scratcher. The Progress Report is included as a formal requirement with a competing continuation (renewal in modern parlance) application. But it has to fit within the page limits, unlike either an Introduction or a List of Publications Resulting (also an obligation of renewals apps) which gets you extra pages.

But the vast majority of NIH R01s include a report on the progress made so far. This is what is known as Preliminary Data! In the 25 page days, I tended to put Preliminary Data in a subsection with a header. Many other applications that I reviewed did something similar. It might as well have been called the Progress Report. Now, I sort of spread Preliminary Data around the proposal but there is a degree to which the Significance and Innovation sections do more or less form a report on progress to date.

There are at least two scenarios where grant writing behavior that I've seen might run afoul of this rule.

There is a style of grant writer that loves to place the proposal in the context of their long, ongoing research program. "We discovered... so now we want to explore....". or "Our lab focuses on the connectivity of the Physio-Whimple nucleus and so now we are going to examine...". The point being that their style almost inevitably requires a narrative that is drawn from the lab as a whole rather than any specific prior interval of funding. But it still reads like a Progress Report.

The second scenario is a tactical one in which a PI is nearing the end of a project and chooses to continue work on the topic area with a new proposal rather than a renewal application. Maybe there is a really big jump in Aims. Maybe it hasn't been productive on the previously proposed Aims. Maybe they just can't trust the timing and surety of the NIH renewal proposal process and need to get a jump on the submission date. Given that this new proposal will have some connection to the ongoing work under a prior award, the PI may worry that the review panel will balk at overlap. Or at anticipated overlap because they might assume the PI will also be submitting a renewal application for that existing funding. In the old days you could get 2 or 3 R01 more or less on the same topic (dopamine and stimulant self-administration, anyone?) but I think review panels are unkeen on that these days. They are alert to signs of multiple awards on too-closely-related topics. IME anyway. So the PI might try to navigate the lack of overlap and/or assure the reviewers that there is not going to be a renewal of the other one in some sort of modestly subtle way. This could take the form of a Progress Report. "We made the following progress under our existing R01 but now it is too far from the original Aims and so we are proposing this as a new project.." is something I could totally imagine writing.

But as we know, what makes sense to me for NIH grant applications is entirely beside the point. The NOT clarifies the rules. Adhere to them.

7 responses so far

"But you are doing fine, what are you complaining about?"

(by drugmonkey) Jul 26 2018

I've been seeing a few Twitter discussions that deal with a person wondering if their struggles in the academy are because of themselves (i.e., their personal merit/demerit axis) or because of their category (read: discrimination). This touches on the areas of established discrimination that we talk about around these parts, including recently the NIH grant fate of ESI applicants, women applicants and POC applicants.

In any of these cases, or the less grant-specific situations of adverse outcome in academia, it is impossible to determine on a case by case basis if the person is suffering from discrimination related to their category. I mean sure, if someone makes a very direct comment that they are marking down a specific manuscript, grant or recommendation only because the person is a woman, or of color or young then we can draw some conclusions. This never* happens. And we do all vary in our treatments/outcomes and in our merits that are intrinsic to ourselves. Sometimes outcomes are deserved, sometimes they vary by simple statistical chance and sometimes they are even better than deserved. So it is an unanswerable question, even if the chances are high that sometimes one is going to be treated poorly due to one's membership in one of the categories against which discrimination has been proven.

These questions become something other than unanswerable when the person pondering them is doing "fine".

"You are doing fine! Why would you complain about mistreatment, never mind wonder if it is some sort of discrimination you are suffering?"

I was also recently struck by a Tweeter comment about suffering a very current discrimination of some sort that came from a scientist who is by many measures "doing fine".

Once, quite some time ago, I was on a seminar committee charged with selecting a year's worth of speakers. We operated under a number of constraints, financial and topic-wise; I'm sure many of you have been on similar committees. I immediately noticed we weren't selecting a gender balanced slate and started pushing explicitly for us to include more women. Everyone sort of ruefully agreed with me and admitted we need to do better. Including a nonzero number of female faculty on this panel, btw. We did try to do better. One of the people we invited one year was a not-super-senior person (one our supposed constraints was seniority) at the time with a less than huge reputation. We had her visit for seminar and it was good if perhaps not as broad as some of the ones from more-senior people. But it all seemed appropriate and fine. The post-seminar kvetching was instructive to me. Many folks liked it just fine but a few people complained about how it wasn't up to snuff and we shouldn't have invited her. I chalked it up to the lack of seniority, maybe a touch of sexism and let it go. I really didn't even think twice about the fact that she's also a person of color.

Many years later this woman is doing fine. Very well respected member of the field, with a strong history of contributions. Sustained funding track record. Trainee successes. A couple of job changes, society memberships, awards and whatnot that one might view as testimony to an establishment type of career. A person of substance.

This person went on to have the type of career and record of accomplishment that would have any casual outsider wondering how she could possibly complain about anything given that she's done just fine and is doing just fine. Maybe even a little too fine, assuming she has critics of her science (which everyone does).

Well, clearly this person does complain, given the recent Twitt from her about some recent type of discrimination. She feels this discrimination. Should she? Is it really discrimination? After all, she's doing fine.

Looping back up to the other conversations mentioned at the top, I'll note that people bring this analysis into their self-doubt musings as well. A person who suffers some sort of adverse outcome might ask themselves why they are getting so angry. "Isn't it me?", they think, "Maybe I merited this outcome". Why are they so angered about statistics or other established cases of discrimination against other women or POC? After all, they are doing fine.

And of course even more reliable than their internal dialog we hear the question from white men. Or whomever doesn't happen to share the characteristics under discussion at the moment. There are going to be a lot of these folks that are of lesser status. Maybe they didn't get that plum job at that plum university. Or had a more checkered funding history. Fewer highly productive collaborations, etc. They aren't doing as "fine". And so anyone who is doing better, and accomplishing more, clearly could not have ever suffered any discrimination personally. Even those people who admit that there is a bias against the class will look at this person who is doing fine and say "well, surely not you. You had a cushy ride and have nothing to complain about".

I mused about the seminar anecdote because it is a fairly specific reminder to me that this person probably faced a lot of implicit discrimination through her career. Bias. Opposition. Neglect.

And this subtle antagonism surely did make it harder for her.

It surely did limit her accomplishments.

And now we have arrived. This is what is so hard to understand in these cases. Both in the self-reflection of self-doubt (imposter syndrome is a bear) and in the assessment of another person who is apparently doing fine.

They should be doing even better. Doing more, or doing what they have done more easily.

It took me a long while to really appreciate this**.

No matter how accomplished the woman or person of color might be at a given point of their career, they would have accomplished more if it were not for the headwind against which they always had to contend.

So no, they are not "doing fine". And they do have a right to complain about discrimination.

__
*it does. but it is vanishingly rare in the context of all cases where someone might wonder if they were victim of some sort of discrimination.
**I think it is probably my thinking about how Generation X has been stifled in their careers relative to the generations above us that made this clearest to me. It's not quite the same but it is related.

9 responses so far

When NIH uses affirmative action to fix a bias

(by drugmonkey) Jul 20 2018

We have just learned that in addition to the bias against black PIs when they try to get research funding (Ginther et al., 2011), Asian-American and African-American K99 applicants are also at a disadvantage. These issues trigger my usual remarks about how NIH has handled observed disparities in the past. In the spirit of pictures being worth more than words we can look up the latest update on success rates for RPG (a laundry list of research grant support mechanisms) broken down by two key factors.
First up is the success rate by the gender of the PI. As you can see very clearly, something changed in 2003. All of a sudden a sustained advantage for men disappeared. Actually two things happened. This disparity was "fixed" and the year after success rates went in the tank for everyone. There are a couple of important observations. The NIH didn't suddenly fix whatever was going on in study section, I guaranfrickentee it. I guarantee there were not also any magic changes in the pipeline or female PI pool or anything else. I guarantee you that the NIH decided to equalize success rates by heavy handed top-down affirmative action policies in the nature of "make it so" and "fix this". I do not recall ever seeing anything formal so, hey, I could be way off base. If so, I look forward to any citation of information showing change in the way they do business that coincided directly with the grants submitted for the FY2003 rounds.
The second thing to notice here is that women's success rates never exceeded that for men. Not for fifteen straight Fiscal Years. This further supports my hypothesis that the bias hasn't been fixed in some fundamental way. If it had been fixed, this would be random from year to year, correct? Sometimes the women's rates would sneak above the men's rates. That never happens. Because of course when we redress a bias, it can only ever just barely reach statistically indistinguishable parity and if god forbid the previously privileged class suffers even the tiniest little bit of disadvantage it is an outrage.
Finally, the fact that success rates went in the tanker in 2004 should remind you that men enjoyed the advantage all during the great NIH doubling! The salad days. Lots of money available and STILL it was being disproportionately sucked up by the advantaged group. You might think that when there is an interval of largesse that systems would be more generous. Good time to slip a little extra to women, underrepresented individuals or the youth, right? Ha.

Which brings me to the fate of first-time investigators versus established investigators. Oh look, the never-funded were instantly brought up to parity in 2007. In this case a few years after the post-doubling success rates went in the toilet but more or less the same pattern. Including the failure of the statistically indistiguishable success rates for the first timers to ever, in 11 straight years of funding, to exceed the rates for established investigators. Because of affirmative action instead of fixing the bias. As you will recall, the head of the NIH at that time made it very clear that he was using "make it so" top-down heavy handed quota based affirmative action to accomplish this goal.

Zerhouni created special awards for young scientists but concluded that wasn't enough. In 2007, he set a target of funding 1500 new-investigator R01s, based on the previous 5 years' average.

Some program directors grumbled at first, NIH officials say, but came on board when NIH noticed a change in behavior by peer reviewers. Told about the quotas, study sections began “punishing the young investigators with bad scores,” says Zerhouni.

"quotas".

I do not recall much in the way of discussing the "pipelines" and how we couldn't possible do anything to change the bias of study sections until a new, larger and/or better class of female or not-previously-funded investigators could be trained up. The NIH just fixed it. ish. permanently.

For FY2017 there were 16,954 applications with women PIs. 3,186 awards. If you take the ~3% gap from the interval prior to 2003, this means that the NIH is picking up some 508 research project grants from women PIs via their affirmative action process. Per year. If you apply the ~6% deficit enjoyed by first time investigators in the salad days you end up with 586 research project grants picked up by affirmative action. Now there will be some overlap of these populations. Women are PI of about 31% of applications in the data for the first graph and first timers are about 35% for the second. So very roughly women might be 181 of the affirmative action newbie apps and newbies might be 178 of the affirmative action women's apps. The estimates are close. So let's say something like 913 unique grants are picked up by the NIH just for these two overt affirmative action purposes. Each and every Fiscal Year.

Because of the fact that, for example, African-American PIs of research grants or K99 apps represent such tiny percentages of the total (2% in both cases), the number of pickups that would be necessary to equalize success rate disparities is tiny. In the K99 analysis, it was a mere 23 applications across a decade. Two per year. I don't have research grant numbers handy but if we use the data underlying the first graph, this means there were about 1,080 applications with African-American PIs in FY2017. If they hit the 19% success rate this would be about 205 applications. Ginther reported about a 13% success rate deficit, working out to 55% of the success rate enjoyed by white applicants at the time. This would correspond to a 10.5% success rate for black applicants now, or about 113 application. So 92 would be needed to make up the difference for African-American PIs assuming the Ginther disparity still holds. This would be less than one percent of the awards made.

Less than one percent. And keep in mind these are not gifts. These are making up for a screwjob. These are making up for the bias. If any applicants from male, established or white populations go unfunded to redress the bias, they are only losing their unearned advantage. Not being disadvantaged.

28 responses so far

Racial Disparity in K99 Awards and R00 Transitions

(by drugmonkey) Jul 19 2018

Oh, what a shocker.

In the wake of the 2011 Ginther finding [see archives on Ginther if you have been living under a rock] that there was a significant racial bias in NIH grant review, the concrete response of the NIH was to blame the pipeline. Their only real dollar, funded initiatives were to attempt to get more African-American trainees into the science pipeline. The obvious subtext here was that the current PIs, against whom the grant review bias was defined, must be the problem, not the victim. Right? If you spend all your time insisting that since there were not red-fanged, white-hooded peer reviewers overtly proclaiming their hate for black people that peer review can't be the problem, and you put your tepid money initiatives into scraping up more trainees of color, you are saying the current black PIs deserve their fate. Current example: NIGMS trying to transition more underrepresented individuals into faculty ranks, rather than funding the ones that already exist.

Well, we have some news. The Rescuing Biomedical Research blog has a new post up on Examining the distribution of K99/R00 awards by race authored by Chris Pickett.

It reviews success rates of K99 applicants from 2007-2017. Application PI demographics broke down to nearly 2/3 White, ~1/3 Asian, 2% multiracial and 2% black. Success rates: White, 31%, Multiracial, 30.7%, Asian, 26.7%, Black, 16.2%. Conversion to R00 phase rates: White, 80%, Multiracial, 77%, Asian, 76%, Black, 60%.

In terms of Hispanic ethnicity, 26.9% success for K99 and 77% conversion rate, neither significantly different from the nonHispanic rates.

Of course, seeing as how the RBR people are the VerySeriousPeople considering the future of biomedical careers (sorry Jeremy Berg but you hang with these people), the Discussion is the usual throwing up of hands and excuse making.

"The source of this bias is not clear...". " an analysis ...could address". "There are several potential explanations for these data".

and of course
"put the onus on universities"

No. Heeeeeeyyyyyuuullll no. The onus is on the NIH. They are the ones with the problem.

And, as per usual, the fix is extraordinarily simple. As I repeatedly observe in the context of the Ginther finding, the NIH responded to a perception of a disparity in the funding of new investigators with immediate heavy handed top-down quota based affirmative action for many applications from ESI investigators. And now we have Round2 where they are inventing up new quota based affirmative action policies for the second round of funding for these self-same applicants. Note well: the statistical beneficiaries of ESI affirmative action polices are white investigators.

The number of K99 applications from black candidates was 154 over 10 years. 25 of these were funded. To bring this up to the success rate enjoyed by white applicants, the NIH need only have funded 23 more K99s. Across 28 Institutes and Centers. Across 10 years, aka 30 funding cycles. One more per IC per decade to fix the disparity. Fixing the Asian bias would be a little steeper, they'd need to fund another 97, let's round that to 10 per year. Across all 28 ICs.

Now that they know about this, just as with Ginther, the fix is duck soup. The Director pulls each IC Director aside in quiet moment and says 'fix this'. That's it. That's all that would be required. And the Directors just commit to pick up one more Asian application every year or so and one more black application every, checks notes, decade and this is fixed.

This is what makes the NIH response to all of this so damn disturbing. It's rounding error. They pick up grants all the time for reasons way more biased and disturbing than this. Saving a BSD lab that allegedly ran out of funding. Handing out under the table Administrative Supplements for gawd knows what random purpose. Prioritizing the F32 applications from some labs over others. Ditto the K99 apps.

They just need to apply their usual set of glad handing biases to redress this systematic problem with the review and funding of people of color.

And they steadfastly refuse to do so.

For this one specific area of declared Programmatic interest.

When they pick up many, many more grants out of order of review for all their other varied Programmatic interests.

You* have to wonder why.
__
h/t @biochembelle

*and those people you are trying to lure into the pipeline, NIH? They are also wondering why they should join a rigged game like this one.

13 responses so far

Zealots

(by drugmonkey) Jul 12 2018

One of my favorite thing about this blog, as you know Dear Reader, is the way it exposes me (and you) to the varied perspectives of academic scientists. Scientists that seemingly share a lot of workplace and career commonalities which, on examination, turn out to differ in both expected and unexpected ways. I think we all learn a lot about the conduct of science in the US and worldwide (to lesser extent) in this process.

Despite numerous pointed discussions about differences of experience and opinion for over a decade now, it still manages to surprise me that so many scientists cannot grasp a simple fact.

The way that you do science, the way the people around you do science and the way you think science should be done are always but one minor variant on a broad, broad distribution of behaviors and habits. Much of this is on clear display from public evidence. The journals that you read. The articles that you read. The ones that you don't but can't possible miss knowing that they exist. Grant funding agencies. Who gets funded. Universities. Med schools within Universities. Research Institutions or foundations. Your colleagues. Your mentors and trainees. Your grad school drinking buddies. Conference friends and academic society behaviors.

It is really hard to miss. IMO.

And yet.

We still have this species of dumbass on the internet that can't get it through his* thick head that his experiences, opinions and, yes, those of his circle of reflecting room buddies and acolytes, is but a drop in the bucket.

And they almost invariable start bleating on about how their perspective is not only the right way to do things but that some other practice is unethical and immoral. Despite the evidence (again, often quite public evidence) that large swaths of scientists do their work in this totally other, and allegedly unethical, way.

The topic of the week is data leeching, aka the OpenAccessEleventy perspective that every data set you generate in your laboratory should be made available in easily understood, carefully curated format for anyone to download. These leeches then insist that anyone should be free to use these data in any way they choose with barely the slightest acknowledgment of the person who generated the data.

Nobody does this. Right? It's a tiny minority of all academic scientific endeavor that meets this standard at present. Limited in the individuals, limited in the data types and limited in the scope even within most individuals who DO share data in this way. Maybe we are moving to a broader adoption of these practices. Maybe we will see significant advance. But we're not there right now.

Pretending we are, with no apparent recognition of the relative proportions across academic science, verges on the insane. Yes, like literally delusional insanity**.

__
*94.67% male

**I am not a psychiatristTM

49 responses so far

« Newer posts Older posts »